

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
1 September 2005 (01.09.2005)

PCT

(10) International Publication Number  
**WO 2005/080386 A1**

(51) International Patent Classification<sup>7</sup>: **C07D 413/14**,  
A61K 31/4545, A61P 25/00, A61K 31/5377, 31/496,  
C07D 401/14

(21) International Application Number:  
PCT/US2005/005216

(22) International Filing Date: 17 February 2005 (17.02.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/545,292 18 February 2004 (18.02.2004) US

(71) Applicants (for all designated States except US): **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE). **NPS PHARMACEUTICALS, INC.** [US/US]; 383 Colow Drive, Salt Lake City, UT 84108 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ARORA, Jalaj** [CA/CA]; 34 Alona Avenue, Cambridge, Ontario N3C 3Y5 (CA). **EDWARDS, Louise** [CA/CA]; NPS Allelix Corp., 6850 Goreway Drive, Mississauga, Ontario L4V 1V7 (CA). **ISAAC, Methvin** [CA/CA]; NPS Allelix Corp., 6850 Goreway Drive, Mississauga, Ontario L4V 1V7 (CA). **KERS, Annika** [SE/SE]; AstraZeneca R & D Headquarters, Global Intellectual Property, S-151 85 Södertälje (SE). **STAAF, Karin** [SE/SE]; AstraZeneca R & D Headquarters, Global Intellectual Property, SE-151 85 Södertälje (SE). **SLASSI, Abdelmalik** [CA/CA]; NPS Allelix Corp., 6850 Goreway Drive, Mississauga, Ontario

L4V 1V7 (CA). **STEFANAC, Tomislav** [CA/CA]; NPS Allelix Corp., 6850 Goreway Drive, Mississauga, Ontario L4V 1V7 (CA). **WENSBO, David** [SE/SE]; AstraZeneca R & D Headquarters, Global Intellectual Property, S-151 85 Södertälje (SE). **XIN, Tao** [CA/CA]; 10 Comoq Avenue, Woodbridge, Ontario L4H 2B1 (CA). **HOLM, Björn** [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: POLYHETEROCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS



(57) Abstract: The present invention relates to new compounds of formula (I), wherein P, Q, X<sup>1</sup>, X<sup>2</sup>, X<sup>3</sup>, X<sup>4</sup>, X<sup>5</sup>, X<sup>6</sup>, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, m, n, and p are as defined as in formula (I), or salts, or hydrates thereof, processes for their preparation and new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds and to the use of said compounds in therapy.